“Sick day” guidance in patients at risk of Acute Kidney Injury:  
a Position Statement from the Think Kidneys Board

As health professionals one of our key aims is to reduce the risk of avoidable harm to our patients. Some people are at increased risk of Acute Kidney Injury (AKI), for example those with Chronic Kidney Disease (CKD), heart failure, or those taking particular medications (1). Many health care professionals provide advice to such patients that certain drugs should be temporarily discontinued during acute intercurrent illnesses, particularly where there is disturbed fluid balance. This advice is commonly described as ‘sick day rules’, similar to those provided to patients with diabetes treated with Insulin.

This Position Statement refers to such guidance given to patients when they are well, about how to manage their own medication should they become unwell. It does not relate to clinical management of known or suspected AKI by health care professionals.

The definition of ‘acute illness’ in this context has to be simple enough to be understood by patients at risk. The NHS Highland definition (2) is a good example:

‘when you are unwell with any of the following;

- vomiting or diarrhoea (unless minor)
- fevers, sweats and shaking’

There are three main reasons for providing such advice:

1. Non-steroidal anti-inflammatory drugs impair renal autoregulation by inhibiting prostaglandin-mediated vasodilatation of the afferent arteriole and may increase the risk of AKI.

2. Drugs that lower blood pressure, or cause volume contraction, might increase the risk of AKI by reducing glomerular perfusion. These drugs include:
   a. ACE inhibitors (ACEI) and Angiotensin Receptor Blockers (ARBs), which reduce systemic blood pressure and also cause vasodilatation of the efferent arteriole, further reducing glomerular perfusion pressure.
b. Diuretics, which can cause a reduction in GFR if their use results in hypovolaemia. This group also includes the mineralocorticoid receptor antagonists spironolactone and eplerenone, used frequently in heart failure.

c. Other blood-pressure-lowering drugs, which will lower systemic blood pressure.

3. Drugs might accumulate as a result of reduced kidney function in AKI, increasing the risks of adverse effects. These drugs include:

a. Metformin, accumulation of which may be associated with an increased risk of type A lactic acidosis in high risk patients.

b. Some sulfonylurea drugs, accumulation of which increase the risk of hypoglycaemia.

c. Trimethoprim, which increases the risk of hyperkalaemia. This drug also interferes with tubular creatinine secretion, and therefore causes a rise in creatinine levels and may result in a ‘false positive’ diagnosis of AKI.

Although the NICE AKI guideline (3) advocates provision of sick day guidance, the evidence that provision of such advice reduces net harm is very weak. The major evidence comes from observational studies and case series that demonstrate an association between receipt of ACEIs, ARBs and NSAIDs (particularly in combination, e.g. ACEI plus NSAID), and a risk of AKI during acute illness, particularly urine infection (4, 5, 6). However, these studies may be confounded by indication. For example patients receive ACEIs or ARBs because they have a pre-existing condition – i.e. heart failure with a poor cardiac output - that is independently associated with an increased risk of AKI; and are clearly subject to publication bias. The largest available study, using a UK primary care dataset, showed only a small increase in the risk of AKI during receipt of an ACEI or ARB compared to receipt of other antihypertensives (adjusted relative risk 1.12, 95% confidence interval 1.07-1.17), with lower risks associated with ACEI/ARB treatment in the populations at greatest risk: for instance, the relative risk of AKI during ACEI/ARB treatment amongst patients with pre-existing chronic kidney disease stage G4 was 0.66 (95% CI 0.44-0.97) (7).

There are potential harms associated with widespread provision of ‘sick day’ rules or guidance, particularly when the patients have not been clinically assessed and where it is unclear at what level of ill health the medication should be discontinued. These include:

1. Decompensated heart failure when drugs blocking the RAAS system and diuretics are discontinued.

2. Acute kidney injury caused by right-sided congestion complicating withdrawal of diuretics, particularly in right heart failure.

3. Development of poorly controlled hypertension with cessation of antihypertensive medication.

4. Reduced adherence to drug treatment which may have been incorrectly described as ‘nephrotoxic’. Patients may consider that the potential harm outweighs the potential benefit and decide to stop taking the drug permanently, even in the absence of, or after recovery from, an acute illness.

5. Patients may over-interpret the advice and stop their drug treatment during even minor illnesses.

6. Patients may not re-start their drug treatment on recovery.

7. The drugs may not be titrated back to the previous evidence-based levels even when
there has been no evidence of AKI.

8. People may self-manage inappropriately and not seek professional help at an appropriate stage.

9. Making changes to regular medication in patients reliant on dosette boxes is complex and can have unintended consequences.

10. Diabetes control may be adversely affected by inappropriate cessation of glucose lowering treatment.

It is also a theoretical possibility that ACEI and ARB treatment might **reduce** the severity or duration of AKI, at least in a subset of patients. These drugs, by causing efferent arteriolar vasodilatation, increase blood flow to the renal tubules: and it is tubular injury that causes persistent AKI and the increased risk of subsequent chronic kidney disease.

A systematic review of the published evidence on this topic found only 6 studies, all in hospital settings. There was low quality evidence that withdrawal of ACEI/ARB prior to coronary angiography and cardiac surgery may reduce the risk of AKI (8). A qualitative study indicated that the concept of temporary cessation is not always a straightforward concept to communicate, particularly with patients deemed at higher risk of AKI and with less capacity to self-manage (9).

This position statement has been agreed by specialists in kidney medicine and also by representatives from primary care. Aligned with NICE Quality Standard 76, the NHS England Think Kidneys Programme Board recommends that health professionals communicate risk of AKI with patients and carers (1). This should include discussion about possible causes including the need to maintain fluid balance during episodes of acute illness. In terms of medicines management, advice from the Think Kidneys Programme Board is that it is reasonable for clinicians to provide sick day guidance on temporary cessation of medicines to patients deemed at high risk of AKI based on an individual risk assessment. However, we consider that investment in a systematic approach to increase uptake of sick day rules guidance by patients should only be undertaken in the context of a formal evaluation.

We welcome comment and debate on this issue, and contact with those people who have already rolled out local programmes, or who have evidence on the implementation and effectiveness of this approach to add to the review.

Please respond to thinkkidneys@renalregistry.nhs.uk

---

3. NICE CG169: Prevention, detection and management of acute kidney injury up to the point of renal replacement therapy. [http://www.nice.org.uk/guidance/cg169](http://www.nice.org.uk/guidance/cg169)


Update to the Position Statement on Sick Day Guidance – November 2015

The authors have reviewed the statement in response to recent evidence and comments and would like to thank those professionals who have contacted the Think Kidneys Programme offering opinions on the Statement.

Both the Think Kidneys team and some of those who have commented, believe that the term ‘Sick Day Rules’ may be unhelpful since it suggests a dogmatic approach to management instead of providing individualised advice. We suggest that ‘Sick Day Guidance’ may be a more helpful term. In addition, there remains the need to characterise Sick Day Guidance, defining the target audience and how it is operationalised.

Although a time series analysis from NHS Highland appears to show a reduction in AKI at around the time of systematic roll-out of 'sick day rules', the fall in heart failure admissions at around the same time raises the possibility of a secular trend or data problem leading to both: it is difficult to explain how advice on temporary withdrawal of ACEIs and ARBs during intercurrent illness would cause a fall in heart failure admissions. A literature review is at present being undertaken to assess the effectiveness of advice given to patients on the reduction of risk of AKI and this will be reported early in 2016.

At present it is recommended that professionals offer advice to individuals considered to be at higher risk of AKI should they become unwell and that the advice should include fluid and medicines management. It should also include advice about assessment of illness severity and when to seek professional help.

It is considered that all antihypertensive medication may increase the risk of AKI. The relative risk of blood pressure therapies is still uncertain and it may be unhelpful to single out ACEIs and ARBs. We would also encourage people to avoid using the term ‘nephrotoxic’ to describe them.

The Think Kidneys team will review their Interim Position Statement on sick day guidance again once we have the results of the full literature review.

Please continue to offer your opinions to help us to develop sick day guidance.

Please respond to thinkkidneys@renalregistry.nhs.uk